Next 10 |
2024-04-09 16:49:42 ET Summary AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonar...
2024-04-09 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-05 09:19:01 ET More on AngioDynamics AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics gets FDA clearance for pulmonary embolism treatment device AngioDynamics Q3 2024 Ear...
2024-04-05 08:34:13 ET More on premarket gainers & stock NuScale Power Shows Too Many Red Flags NuScale Power: Attractive, Yet High-Risk Nuclear Energy Business NuScale Power Corporation (SMR) Q3 2023 Earnings Call Transcript EIGR, ADXN and BROG are among...
2024-04-05 08:00:12 ET Steven Lichtman from Oppenheimer issued a price target of $12.00 for ANGO on 2024-04-05 07:15:00. The adjusted price target was set to $12.00. At the time of the announcement, ANGO was trading at $6.4. The overall price target consensus is at $22.0...
2024-04-04 17:29:32 ET Gainers: Candel Therapeutics ( CADL ) +38% . Grindrod Shipping ( GRIN ) +28% . AngioDynamics ( ANGO ) +14% . Petco Health and Wellness Company ( WOOF ) +7% . Marinus Pharmaceuticals ( MRNS ) +5% . ...
2024-04-04 11:11:03 ET AngioDynamics Inc. (ANGO) Q3 2024 Earnings Conference Call April 4, 2024 8:00 am ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice President, Chief Financial Officer Conference Call...
2024-04-04 07:41:17 ET AngioDynamics ( NASDAQ: ANGO ) has secured a label expansion for its AlphaVac F1885 System from the U.S. Food and Drug Administration (FDA).... Read the full article on Seeking Alpha For further details see: AngioDynamics gets FDA clearance...
2024-04-04 07:04:49 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics Q3 2024 Ear...
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
News, Short Squeeze, Breakout and More Instantly...
2024-04-09 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Although U.S. stocks closed little changed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their co...
2024-04-05 08:00:12 ET Steven Lichtman from Oppenheimer issued a price target of $12.00 for ANGO on 2024-04-05 07:15:00. The adjusted price target was set to $12.00. At the time of the announcement, ANGO was trading at $6.4. The overall price target consensus is at $22.0...